Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz for Persistent Nonsuppressible HIV Viremia
NCT06823596Recruiting
- Sponsor
- University of Toronto
- Start
- Jan 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of efavirenz in human immunodeficiency virus infection (HIV), sponsored by University of Toronto. Primary endpoint: Change in plasma viremia at 8 weeks. Started Jan 2025; status: recruiting.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06823596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823596.